Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-ipilimumab PET in Metastatic Melanoma
NCT03313323Phase 2Unknown
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2017
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of 89Zr-ipilimumab in melanoma, sponsored by Amsterdam University Medical Center. Status: unknown.
02
Drugs
89Zr-ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03313323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03313323.